In this trial of 156 patients on low-dose ASA (80mg) who developed peptic-ulcer-related GI bleeding, they were randomized, after endoscopic control of the bleeding, to continue ASA or placebo. Recurrent GI bleeding at 30-days was significantly higher in the ASA group (10% vs 5%), but the ASA group had lower 8-week all-cause mortality (1% vs 13%). Although ASA cessation after peptic-ulcer bleeding is associated with lower 30-day bleeding risk, it is also associated with higher 8-week mortality (abstract). It may be beneficial to immediately re-start the ASA in some patients.
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
This large trial of patients with a relative contraindication for enteral feeds were randomized to early TPN or usual care. There were no differences in the groups in 60 day mortality or LOS, but those on TPN did have a shorter time ventilated and less muscle/fat loss. It is unclear based on this trial if […]